Investigation announced for Investors in shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) over takeover

An investigation was announced concerning whether the takeover of Alexion Pharmaceuticals, Inc. is unfair to NASDAQ: ALXN stockholders.

Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and currently hold any of those NASDAQ: ALXN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Alexion Pharmaceuticals, Inc. breached their fiduciary duties owed to NASDAQ: ALXN investors in connection with the proposed acquisition.

Boston, MA based Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. On Dec. 12, 2020, AstraZeneca and Alexion Pharmaceuticals, Inc. have entered into an agreement for AstraZeneca to acquire Alexion. Under the terms of the proposed transaction Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share.
Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share.

However, given that at least one analyst has set the high target price for NASDAQ: ALXN shares at $200.00 per share, the investigation concerns whether the offer is unfair to NASDAQ: ALXN stockholders. More specifically, the investigation concerns whether the Alexion Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Alexion Pharmaceuticals, Inc. reported that its annual Total Revenue rose from over $4.13 billion in 2018 to over $4.99 billion in 2019, and that its EBIT rose from $340.4 million in 2018 to over $2.25 billion in 2019.

Those who are current investors in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.